Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Ryden

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Giornale Italiano Di Cardiologia (2006)|April 25, 2013
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)]Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 17, 2016
[European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]Joep Perk, Guy De Backer, Helmut Gohlke, et al.
European Heart Journal|May 5, 2012
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
International Journal of Behavioral Medicine|October 25, 2012
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Atherosclerosis|June 16, 2012
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Cardiovascular Diabetology|March 17, 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomesOliver Schnell, Tadej Battelino, Richard Bergenstal, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Circulation|April 1, 2020
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS TrialDeepak L Bhatt, John W Eikelboom, Stuart J Connolly, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
Giornale Italiano Di Cardiologia (2006)|April 25, 2013
[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)]Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 17, 2016
[European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]Joep Perk, Guy De Backer, Helmut Gohlke, et al.
European Heart Journal|May 5, 2012
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
International Journal of Behavioral Medicine|October 25, 2012
European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Atherosclerosis|June 16, 2012
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)Joep Perk, Guy De Backer, Helmut Gohlke, et al.
Cardiovascular Diabetology|March 17, 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomesOliver Schnell, Tadej Battelino, Richard Bergenstal, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
Pageof 5